Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemzoparlimab in Advanced Solid Tumors and Lymphoma
NCT03934814Phase 1Completed
- Sponsor
- I-Mab
- Start
- Apr 2019
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of lemzoparlimab in solid tumor, lymphoma, diffuse large B-cell lymphoma (DLBCL) and 5 more (4 arms), sponsored by I-Mab. Primary endpoints: Dose Limiting Toxicities at 28 days, Incidence and Severity of Adverse Events and 2 more. Started Apr 2019; status: completed.
02
Drugs
lemzoparlimab
03
Conditions
solid tumorlymphomadiffuse large B-cell lymphoma (DLBCL)indolent B-cell lymphomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03934814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934814.